A Cure for Sickle Cell? Science Says Yes. Your Wallet May Disagree.

For the estimated 100,000 Americans living with sickle cell disease, June’s awareness month comes with news that once sounded impossible: a functional cure now exists.

The harder question is who can get it.

Sickle cell disease is an inherited blood disorder that changes the shape of red blood cells. Instead of moving smoothly through the body, the cells can become stiff and crescent-shaped, like a sickle. These misshapen cells can clump together and block blood flow.

The result can be devastating. People with sickle cell disease may suffer severe pain crises, organ damage, strokes, infections, and shortened life expectancy. The disease affects people around the world and is especially common among people of African ancestry.

For decades, treatment focused on managing symptoms. Some medicines reduce pain crises. Blood transfusions helped certain patients. A bone marrow transplant could offer a cure, but it came with major risks and required a closely matched donor. For many patients, that was not a realistic option.

Then came gene therapy.

In late 2023, the U.S. Food and Drug Administration approved two major treatments for sickle cell disease: Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia from bluebird bio.

Casgevy made history as the first FDA-approved treatment to use CRISPR gene-editing technology. CRISPR is often described as a set of molecular scissors because it allows scientists to make precise changes to DNA.

Both therapies use a patient’s own stem cells. Doctors collect the cells, send them to a laboratory, and genetically modify them. The patient then receives chemotherapy to clear space in the bone marrow before the repaired cells are infused back into the body. The goal is for those cells to produce healthier red blood cells and prevent the painful blockages that define the disease.

Clinical results have been remarkable. In trials, many patients treated with Casgevy went at least a year without severe pain crises. Lyfgenia also showed strong results in reducing painful episodes.

For patients and families, that is life-changing science.

But the price is staggering.

Casgevy has a list price of about $2.2 million for a one-time treatment. Lyfgenia is priced at about $3.1 million. Those figures do not include all related hospital care, chemotherapy, monitoring and follow-up treatment.

The cost is not the only barrier. Gene therapy is complex. Patients may need to spend weeks in the hospital and months recovering. Treatment must be offered at specialized medical centers. Families may face travel, time off work, child care needs, and other expenses that insurance does not always fully cover.

That creates a painful reality: the cure exists, but access is uneven.

The federal government has been working to address that gap. Medicaid programs and federal health officials have explored payment models that tie the high cost of treatment to patient outcomes. The goal is to help states cover gene therapies without overwhelming their budgets.

That could matter greatly because many people with sickle cell disease rely on Medicaid for health coverage. Without public insurance support, the newest treatments could remain out of reach for patients who need them most.

The science is still young. Researchers will continue to track patients for long-term safety and effectiveness. Doctors will also need to determine which patients are the best candidates for these treatments.

Still, the moment is historic.

For generations, sickle cell disease has meant pain, uncertainty, and limited options. Now, for the first time, gene therapy offers some patients the possibility of living without the disease’s most severe attacks.

Science has opened the door.

The next challenge is making sure patients can walk through it.